Notable Labs hopes for success with Boehringer’s failed AML drug

Notable Labs hopes for success with Boehringer’s failed AML drug

Submitted by admin on February 23, 2024 - 10:35am
Source: 
Clinical Trials Arena
News Tags: 
Notable Labs
Boehringer Ingelheim
AML
volasertib
artificial intelligence
Headline: 
Notable Labs hopes for success with Boehringer’s failed AML drug
snippet: 

Volasertib was being developed by Boehringer Ingelheim but the company discontinued the product after a Phase III study in AML failed.

Do Not Allow Advertisers to Use My Personal information